Suggestions
John Gordon
Professor Emeritus; co-Founder Celentyx Ltd; B-cell aficionado
John Gordon is a prominent figure in the field of immunology, currently serving as Professor Emeritus at the University of Birmingham. He has made significant contributions to cellular immunology and is recognized as an authority on immune cell biology and immune-mediated diseases.
Academic and Professional Background
- Position: Professor Emeritus of Cellular Immunology.
- Former Role: Head of the College of Medical and Dental Sciences Graduate School at the University of Birmingham.
- Co-founder and Chief Scientific Officer (CSO): Celentyx Ltd, a company focused on advancing immunotherapy and cancer research.
- Visiting Professor: Raine Visiting Professor at the University of Western Australia.
Research Contributions
John Gordon has been influential in pioneering the field of Neuro-Immuno-Pharmacology and has a notable track record in translational medicine. His work is highly cited, underscoring his impact on the scientific community. He has been involved in various research areas including:
- Cell Biology
- Hematology
- Immunology
- Pharmacology
Recent Activities
Gordon continues to engage with current research topics, particularly in cancer immunology, as evidenced by his recent posts on LinkedIn, where he discusses advancements in immunotherapy and its applications in both canine and human contexts.123
His expertise and ongoing contributions make him a key figure in advancing our understanding of immune responses and their implications for medical science.
Highlights
#IgE | Time to "UNSWEETEN" the #TherapeuticAntibody Pill 🤔 | Systematic mutational analysis reveals essential role of N275 in IgE #stability | No "Sugar-Coating" of Surprise Findings from Achim Doerner & Co. in new online study |
Therapeutic antibodies have predominantly been IgG-based. However, the ongoing clinical trial of MOv18 IgE has highlighted the potential of using IgE antibodies in cancer therapy. While extensive studies targeting IgG glycosylation resulted in a rational basis for the development of enhanced biotherapeutics, IgE glycosylation remains an area with limited analyses.
Previous studies on the role of IgE glycosylation present conflicting data with one study emphasizing the importance of N275 and T277 residues for FcεRI binding whereas another asserts the nonsignificance of IgE glycosylation in receptor interaction. While existing literature underscores the significance of glycans at the N275 position for binding to FcεR1 receptor and initiation of anaphylaxis, the role of other IgE glycosylation sites in folding or receptor binding remains elusive.
This study* from Shikha K, Sanjay Ghosh, et al systematically investigates the functional significance of N-linked glycosylation sites in the heavy chain of IgE which validates the pivotal role of N275 residue in IgE secretion and stability. Replacement of this asparagine to non-amine group moieties does not affect IgE function in vitro, yet substitution with aspartic acid compromises antibody yield. The deglycosylated IgE variant exhibits superior efficacy, challenging the conventional importance of glycosylation for effector function.
In summary, this study unveils an intricate relationship between N-glycosylation sites and the structural–functional dynamics of IgE antibodies. Furthermore, it offers novel insights into the IgE scaffold, paving the way for the development of more effective and stable IgE-based therapeutics.
*https://lnkd.in/e5yU6Mnb; (full text available at https://lnkd.in/eztiBM3R)
Celentyx Ltd #immunooncology www.celentyx.com
Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady
Dr Neil Bodie
FIGURE | Upper: Schematic diagram showing the engineered IgE variants | Lower: Mechanism of cytotoxicity mediated by MOv18 IgE (taken from Sophia N Karagiannis & Co. https://lnkd.in/eUnGRRKh) |
#NaCl in the #TumorMicroEnvironment enhances the Metabolic Fitness & Cytotoxicity of #Tcells | 'Cheap-as-Chips' ex vivo conditioning for #CARTcells | Breaking Nature #Immunology Study is truly "Worth Its #Salt" 👏 | #TME |
The efficacy of antitumor immunity is associated with the metabolic state of cytotoxic T cells, which is sensitive to the tumor microenvironment. Whether ionic signals affect adaptive antitumor immune responses is unclear.
In the present study*, a team led by Christina Zielinski show that there is an enrichment of sodium in solid tumors from patients with breast cancer. Sodium chloride (NaCl) enhances the activation state and effector functions of human CD8+ T cells, which is associated with enhanced metabolic fitness. These NaCl-induced effects translate into increased tumor cell killing in vitro and in vivo.
Mechanistically, NaCl-induced changes in CD8+ T cells are linked to sodium-induced upregulation of Na+/K+-ATPase activity, followed by membrane hyperpolarization, which magnifies the electromotive force for T cell receptor (TCR)-induced calcium influx and downstream TCR signaling.
It is therefore proposed that NaCl is a positive regulator of acute antitumor immunity that might be modulated for ex vivo conditioning of therapeutic T cells, such as CAR T cells.
*https://lnkd.in/ehiuAi7s
Celentyx Ltd #immunooncology www.celentyx.com
Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady
FIGURE | Overview of molecular mechanism of NaCl-induced T cell hyperactivation |
